A new scientific assessment published in the leading scientific journal, ‘Regulatory Toxicology & Pharmacology’ has reinforced the safety of titanium dioxide (TiO2).
An extensive ‘weight of evidence’ assessment of the genotoxicity of titanium dioxide, initiated by the Titanium Dioxide Manufacturers Association (TDMA) and conducted by an independent expert panel of toxicologists, has concluded that there is no evidence to support claims that TiO2 has a direct genotoxic effect in either its nano or microforms. The TDMA welcomes these findings.
Following the publication of the review, Dr David Lockley, chair of the TDMA’s Scientific Taskforce, said: “The conclusions of the expert panel mark a key milestone that reinforces a growing scientific consensus around the safety of TiO2. This confirms once more the need for a review of the EFSA’s opinion on E171 to ensure that the EU regulation is well-grounded in the available scientific evidence.”